Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Excretion Balance and PK of [14C]-Sodium Valproate
NCT03681158Phase 1Completed
- Sponsor
- Sanofi
- Start
- Oct 2018
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of valproic acid in epilepsy, sponsored by Sanofi. Primary endpoints: Percentage of radioactive dose excreted in urine and feces, Assessment of key metabolite(s) of sodium valproate and 5 more. Started Oct 2018; status: completed.
02
Drugs
valproic acid
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT03681158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03681158.